Berlin (ots) - The new compounds will provide a "full time"
protection of neurons against aging and degeneration. Continuous
administration technologies, which are one of the core competencies
of Axxonis Pharma AG, will additionally enable the concept of 24
hours protection. This is a completely new and innovative approach in
radical scavenging therapy and in the therapy of neurological
disorders induced by oxidative stress.
The new drugs in combination of non-invasive transdermal or
minimal invasive (subcutaneous minipump) application methods will
establish new potent neuroprotective therapies for patients suffering
from Parkinson´s disease, Alzheimer´s disease, Huntington´s disease,
Amyotrophic Lateral Sclerosis or Multiple System Atrophy or other
neurological degenerative diseases induced by chemical radicals.
Axxonis Pharma AG has recently submitted Lisuride transdermal and
subcutaneous drug products (Nenad®) for centralized EU procedure for
continuous dopaminergic stimulation therapy of M. Parkinson and
related disorders. Lisuride is known as a potent radical scavenger
both in vitro and in vivo with strong antioxidant and neuroprotective
effects in vulnerable CNS cell populations.
The new compounds which come from a joint research project, funded
in part with financial means from the EU, between the Institute of
Pharmacy (Prof. H.H. Pertz) of the Freie Universität Berlin, Germany,
and Alfarma s.r.o., Cernosice, Czech Republic will extend
significantly the portfolio of Axxonis Pharma AG and will
substantiate long term growth.
ots Originaltext: Axxonis Pharma AG
Im Internet recherchierbar: http://www.presseportal.ch
Dr. med. Antje Müller-Schubert
Clinical Research & Medical Relations
axxonis Pharma AG
Schöneberger Straße 15
D - 10963 Berlin
phone: +49 (0)30 - 269 34 29 14
fax: +49 (0)30 - 269 34 29 22
To learn more abaout axxonis: